Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659107 | 0.87 | MAP3K5 (0.49) | NTRK1MAP3K5MAPTRAB9A | |
| SCHEMBL24571464 | 0.82 | MAPT (0.50) | NTRK1GRM5MAPTPOLBRAB9A | |
| SCHEMBL29403364 | 0.82 | MAPT (0.50) | NTRK1GRM5MAPTPOLBRAB9A | |
| SCHEMBL22658991 | 0.81 | BRAF (0.50) | MAP3K5MAPTLMNA | |
| SCHEMBL29403375 | 0.80 | NTRK1 (0.49) | NTRK1GRM5MAPTRAB9A | |
| SCHEMBL22659299 | 0.80 | NTRK1 (0.49) | NTRK1GRM5MAPTRAB9A | |
| SCHEMBL22659088 | 0.80 | MAP3K5 (0.45) | NTRK1MAP3K5RAB9A | |
| SCHEMBL22659309 | 0.79 | HPGDS (0.63) | MAP3K5RAB9A | |
| SCHEMBL2858001 | 0.78 | GRM5 (0.70) | NTRK1GRM5MAPTPOLBLMNA | |
| SCHEMBL22659082 | 0.76 | MAPK14 (0.53) | NTRK1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | NTRK1 2504/4885MAP3K5 1871/4885GRM5 746/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | NTRK1 2504/4885MAP3K5 1871/4885GRM5 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.